0001193125-26-097478
SEC filingARS Pharmaceuticals, Inc. reported a net loss of $171.3 million for fiscal year 2025, a significant decline from a net income of $8.0 million in the prior year. Total revenue was $84.3 million, a 5% decrease from $89.1 million in FY 2024. This revenue consisted of $72.2 million in net product sales from the U.S. launch of neffy, $9.7 million from collaboration agreements, and $2.4 million from supply agreements. The substantial net loss was driven by a $230.1 million increase in selling, general, and administrative expenses, primarily for marketing and sales force expansion, and a $19.4 million increase in cost of goods sold. The company ended the year with $245.0 million in cash, cash equivalents, and short-term investments, and an accumulated deficit of $294.6 million. Management believes current resources are sufficient to meet cash requirements for at least the next three years.
ARS Pharmaceuticals, Inc. (SPRY) reported a challenging fiscal year 2025 with a net loss of $171.3 million, a stark reversal from the net income of $8.0 million achieved in FY 2024. Total revenue declined 5% year-over-year to $84.3 million from $89.1 million. The significant loss was primarily driven by a substantial increase in operating expenses, which totaled $263.7 million compared to $92.2 million in the prior year. This increase was fueled by aggressive commercialization efforts for neffy, including a major expansion of marketing activities and sales force infrastructure. The company's cash position remains substantial at $245.0 million in cash, cash equivalents, and short-term investments as of December 31, 2025, though this represents a decrease from the prior year-end balance.
Revenue for FY 2025 was comprised of three main streams: product revenue, collaboration revenue, and supply revenue. Net product revenue from U.S. sales of neffy was $72.2 million, representing the company's first full year of commercialization following the FDA approval in August 2024. Revenue under collaboration agreements was $9.7 million, a significant decrease from $81.5 million in FY 2024, which included a large upfront payment from the ALK Collaboration Agreement. Revenue under supply agreements contributed $2.4 million. The year-over-year revenue decline reflects the non-recurring nature of the large upfront license fee recognized in the prior period, partially offset by the ramp-up of product sales.
The company's gross margin declined to 75.8% in FY 2025 from 98.9% in FY 2024. This decrease is primarily attributable to the recognition of cost of goods sold totaling $20.4 million as product sales commenced, compared to minimal costs in the prior period before commercialization. The operating loss was $179.4 million, resulting in an operating margin of -212.9%. This significant operating loss reflects the company's substantial investments in selling, general and administrative expenses, which increased to $230.1 million from $71.7 million in the prior year, driven by marketing campaigns, sales force expansion, and pre-commercial launch activities.
Net cash used in operating activities was $170.9 million for FY 2025, compared to net cash provided by operating activities of $13.5 million in the prior year. This negative cash flow was primarily driven by the net loss and increases in working capital, particularly inventories and accounts receivable. The company strengthened its balance sheet through financing activities, including $96.3 million in net proceeds from a term loan under a new credit agreement. Total assets were $327.7 million as of December 31, 2025, with current assets of $284.9 million. Total liabilities were $213.4 million, including $96.4 million in term loans. Stockholders' equity was $114.3 million.
Management believes that existing cash, cash equivalents, short-term investments, and revenues from product sales and collaboration agreements will be sufficient to meet anticipated cash requirements through at least the next three years. The company plans to continue its commercialization efforts for neffy in the U.S., including expanding its sales force to approximately 150 individuals beginning in the second quarter of 2026. International expansion continues through partners in Europe, Japan, Australia, and China. The company is also conducting a Phase 2b clinical trial for chronic spontaneous urticaria, with interim data anticipated in the second half of 2026. Key risks include the company's ability to achieve profitability, dependence on third-party manufacturers, and intense competition in the epinephrine market.